ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Abstract : INTRODUCTION: Tumor-initiating cells (TICs), aka "cancer stem cells", are believed to fuel tumors and to sustain therapy resistance and systemic metastasis. Breast cancer is the first human carcinoma in which a subpopulation of cells displaying a specific CD44+/CD24-/low/ESA+ antigenic phenotype was found to have TIC properties. However, CD44+/CD24-/low/ESA+ is not a universal marker phenotype of TICs in all breast cancer subtypes. The aim of this study was to identify novel antigens with which to isolate the TIC population of the basal-A/basal-like breast cancer cell lines. METHODS: We used polychromatic flow-cytometry to characterize the cell surface of several breast cancer cell lines that may represent different tumor molecular subtypes. We next used fluorescence-activated cell sorting to isolate the cell subpopulations of interest from the cell lines. Finally, we explored the stem-like and tumorigenic properties of the sorted cell subpopulations using complementary in vitro and in vivo approaches: mammosphere formation assays, soft-agar colony assays, and tumorigenic assays in NOD/SCID mice. RESULTS: The CD44+/CD24+ subpopulation of the BRCA1-mutated basal-A/basal-like cell line HCC1937 is enriched in several stemness markers, including the ABCG2 transporter (i.e., the CD338 antigen). Consistently, CD338-expressing cells were also enriched in CD24 expression, suggesting that coexpression of these two antigenic markers may segregate TICs in this cell line. In support of ABCG2 expression in TICs, culturing of HCC1937 cells in ultra-low adherent conditions to enrich them in precursor/stem-cells resulted in an increase in CD338-expressing cells. Furthermore, CD338-expressing cells, unlike their CD338-negative counterparts, displayed stemness and transformation potential, as assessed in mammosphere and colony formation assays. Lastly, CD338-expressing cells cultured in ultra-low adherent conditions maintained the expression of CD326/EpCAM and CD49f/α6-integrin, which is a combination of antigens previously assigned to luminal progenitors. CONCLUSION: Collectively, our data suggest that CD338 expression is specific to the tumor-initiating luminal progenitor subpopulation of BRCA1-mutated cells and is a novel antigen with which to sort this subpopulation.
Type de document :
Article dans une revue
Molecular Cancer, BioMed Central, 2014, 13 (1), pp.213. 〈10.1186/1476-4598-13-213〉
Liste complète des métadonnées

Littérature citée [62 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01073838
Contributeur : Christine Dupuis <>
Soumis le : vendredi 10 octobre 2014 - 15:11:23
Dernière modification le : mardi 12 juin 2018 - 11:29:29
Document(s) archivé(s) le : dimanche 11 janvier 2015 - 11:01:19

Fichier

1476-4598-13-213.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Felicia Leccia, Luigi Del Vecchio, Elisabetta Mariotti, Rosa Di Noto, Anne-Pierre Morel, et al.. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.. Molecular Cancer, BioMed Central, 2014, 13 (1), pp.213. 〈10.1186/1476-4598-13-213〉. 〈inserm-01073838〉

Partager

Métriques

Consultations de la notice

140

Téléchargements de fichiers

157